Today’s pharmaceutical companies must manage tight timelines and high demand for products, as well as shifting regulatory requirements and an increasingly complex global supply chain. How can contract development and manufacturing organizations (CDMOs) rise to this challenge and provide the support they need?
In this podcast with PharmaSource, Tommy Shornak, Senior Vice President, Sterile Injectables, discusses the steps that Kindeva is taking to become a world-leading proactive partner, offering comprehensive CDMO services to companies navigating a complex outsourcing landscape.
At the core of the strategy is a $200 million investment in our state-of-the-art Bridgeton facility, which delivers comprehensive sterile fill finish capability as well as long-term regulatory compliance. With fully Annex 1-compliant infrastructure and four automated filling lines, Bridgeton enables Kindeva to prepare proactively for tomorrow’s market needs.
Tommy also covers other ways that Kindeva is positioning itself as a one-stop partner for drug sponsors, including:
- Developing a no-single-source strategy to manage supply chain uncertainty
- Adopting data transparency in partnerships
- Evolving commercial models to provide sponsors with added flexibility
- Integrating sustainability into daily operations
He also discusses what true partnership looks like in practice and what CDMOs need to do to separate themselves from competitors over the next few years.
Listen to the podcast to discover how Kindeva is setting a new standard for proactive, flexible CDMO partnerships.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
What’s behind the decisions shaping successful fill finish programs?
Advanced equipment and available cleanroom capacity are important considerations when choosing a sterile fill finish CDMO partner, but they only form part of the decision. As a drug program nears cGMP manufacturing, careful consideration of technical, quality, and operational readiness is essential, as it shapes how confidently a program can progress. These considerations take place […]
Learn More
Building sterile injectable manufacturing capacity for growing GLP-1 demand
Glucagon-like peptide-1 (GLP-1) receptor agonists are being prescribed more frequently, increasing pressure on sterile injectable manufacturing networks. To effectively serve expanding patient populations, developers must increase output while maintaining product quality and regulatory compliance without disrupting the supply of other therapies. Meeting the growing GLP-1 demand requires manufacturing models that can manage high-volume programs alongside […]
Learn More
Meeting the challenges of fill finish manufacturing
How flexible infrastructure and early manufacturing expertise can help drug developers respond to changing demand With rising demand for glucagon-like peptide-1 (GLP-1) medicines, continued progress in biologics and the expansion of self-administered treatments, new expectations are being placed on sterile fill finish operations. Manufacturers must accommodate different container formats and production volumes while maintaining consistent […]
Learn More
Parenteral precision: Upstream formulation handling before sterile fill finish
Parenteral precision is a blog series exploring the controls, technologies and design decisions that shape modern parenteral manufacturing. Each article looks at one capability through a practical lens: what it is, how it works, who it supports and why it matters. In our first blog, we explored how sterile fill finish operations are designed around […]
Learn More
Delivering tomorrow’s injectables, today
Injectable therapies are entering a new phase of complexity. Biologics, personalized medicines and combination products are increasing demand for delivery systems that must adapt to more diverse formats and patient needs. Expectations around speed and compliance also continue to rise across the development lifecycle, placing greater pressure on how these systems are designed and scaled. […]
Learn More
Q&A: Navigating tech transfer and production pitfalls
Successful tech transfer alignment requires robust risk management and precise operational planning. When communication gaps or unforeseen supply chain hurdles emerge, project timelines and product quality are often the first to be affected. In this Q&A, we explore the common pitfalls of pharmaceutical tech transfers, including how to protect critical milestones without compromising safety and […]
Learn More
Webinar | Beyond the filling suite: How modular facility design supports sterile manufacturing success
Sterile manufacturing requirements are fast evolving, which means that many organizations are reassessing whether their legacy facilities can support future operational and regulatory demands. In this webinar, John Wichelt, Vice President and General Manager at Kindeva’s Bridgeton site, explores what a modern sterile fill finish facility needs to look like in this new era. Drawing […]
Learn More
What does Annex 1 mean for sterile drug product manufacturing?
Annex 1 compliance remains a key priority for companies working in sterile drug product manufacturing. But recognizing how fundamentally expectations around sterility assurance have changed may be the most significant challenge companies face. Revisions to the EU GMP Annex 1 requirements now move beyond individual compliance activities and place greater emphasis on how contamination risks […]
Learn More
Explore our world-class sterile injectable facility in Bridgeton, Missouri | Video tour
Spanning over 155,000 sq. ft. of dedicated aseptic operations space, our Bridgeton, MO facility brings together leading expertise, advanced automation and Annex 1-compliant isolator technology to help support growing global demand for sterile injectables. Designed to deliver excellence from floor to ceiling, Bridgeton seamlessly connects development and delivery through flexible fill finish infrastructure that helps […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.